Two kinds of skin reaction in the documents
The Trulicity® documents separate allergic reactions that affect the whole body from reactions where the injection was given. [1][3] The US label lists hypersensitivity among its warnings, describes systemic reactions such as severe hives, widespread rash and swelling of the face or lips in 0.5% of adults in trials, and adds postmarketing reports of anaphylaxis and angioedema. [1] The EU summary classes hypersensitivity as uncommon and anaphylactic reaction and angioedema as rare, both taken from post-marketing reports. [3] Canada lists rash, itching and contact dermatitis among less common trial events. [4]
| Reaction | Rate or class | Comparison | Source |
|---|---|---|---|
| Systemic hypersensitivity (hives, widespread rash, facial or lip swelling), adults | 0.5% | — | US label 6.1 [1] |
| Injection-site reactions (rash, redness), adults | 0.5% | Placebo 0.0% | US label 6.1 [1] |
| Injection-site reactions, ages 10–17 | 3.9% (0.75 mg), 3.8% (1.5 mg) | Placebo 2.0% | US label 6.1 [1] |
| Hypersensitivity | Uncommon (≥1/1,000 to <1/100) | — | EU Table 1 [3] |
| Anaphylactic reaction; angioedema | Rare (≥1/10,000 to <1/1,000) | Post-marketing | EU Table 1 [3] |
| Rash, pruritus, contact dermatitis | Less common, no rate | — | Canada 8.3 [4] |
What studies and case reports add
A cohort study in three large US insurance databases followed 696,089 new users of GLP-1 medicines with type 2 diabetes. Anaphylaxis occurred in 3.9 per 10,000 person-years on dulaglutide, similar to 3.6 on semaglutide and 5.1 on liraglutide, and the authors concluded that anaphylaxis is rare across the class. [6]
A 2026 meta-analysis of randomised trials found that GLP-1 medicines raise the risk of injection-site reactions compared with other treatments, while body-wide skin events were infrequent and not significantly increased. [5] In US adverse event reports, dulaglutide showed a signal for bleeding at the injection site. [5] Another FAERS analysis found the lowest proportion of skin-related reports with dulaglutide among four GLP-1 medicines. [9]
Individual cases show what a drug rash can look like. One report described a man who developed a rash on the abdomen after his dulaglutide dose was raised; it cleared within days of stopping. [7] Another described a measles-like (morbilliform) eruption, which the authors called very rare. [8] Single cases cannot give a frequency, but they show why a new rash after a dose change is worth reporting.
Local reaction or allergy?
- Local: redness, a small rash, itching or a bruise limited to where you injected. The EU summary says injection-site reactions that may be immune-related were usually mild. [3] The Canadian monograph notes they were more frequent in the small group who developed antibodies to dulaglutide. [4]
- Allergic, body-wide: hives or rash away from the injection site, widespread itching, or swelling of the face, lips, tongue or throat. [2][3]
- Severe allergy (anaphylaxis): symptoms usually develop within seconds or minutes and can include trouble breathing, wheezing, swelling, dizziness, a racing heart, nausea or vomiting and collapse. [12]
- History matters: the label advises caution if you have had angioedema or anaphylaxis with another GLP-1 medicine, because it is not known whether that predicts a reaction to Trulicity®. [1]
Rashes that are not from Trulicity®
MedlinePlus explains that many rashes are dermatitis, an inflammation of the skin, often caused by contact with soaps, cosmetics, detergents, latex, clothing dyes or plants. [11] Eczema, psoriasis, seborrhoeic dermatitis, shingles, insect bites, infections and other medicines are common causes, and hives can also follow infections or stress. [10][11]
Because Trulicity® is often added to several other diabetes, blood pressure and cholesterol medicines, a new rash may come from something else started around the same time. MedlinePlus asks you to contact your provider about a rash when taking a new medicine and not to stop any medicine without talking to them. [11]
What the guidance describes
For a serious allergic reaction, the Medication Guide asks you to stop Trulicity® and get medical help right away. [2] The label adds that anyone who has had a serious allergic reaction to dulaglutide should not use it again. [1]
For mild rashes, MedlinePlus describes gentle skin care: avoiding scrubbing, using mild cleansers and lukewarm water, patting dry, stopping recently added cosmetics and leaving the area open to the air. It mentions non-prescription hydrocortisone cream and oral antihistamines for itch; ask a pharmacist before using them. [11] Rotating injection sites each week is part of the Trulicity® instructions. [2]
Trulicity® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- A swollen face, lips, tongue or throat, difficulty breathing or swallowing, collapse or a very rapid heartbeat
Contact: Stop Trulicity® and call emergency services (911 / 112)
- Severe rash or itching, or hives with rapid swelling
Contact: Stop Trulicity® and get medical help right away
Today
- Rash with fever, joint pain or a sore throat, or red streaks and tenderness suggesting infection
Contact: Your provider
MedlinePlus [11]